50,001 Shares in Palvella Therapeutics, Inc. $PVLA Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC purchased a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 50,001 shares of the company’s stock, valued at approximately $7,641,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Palvella Therapeutics during the 2nd quarter worth $140,343,000. Summit Partners Public Asset Management LLC increased its holdings in shares of Palvella Therapeutics by 1,016.0% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after purchasing an additional 354,525 shares during the period. Vanguard Group Inc. raised its holdings in Palvella Therapeutics by 202.0% in the 3rd quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after acquiring an additional 330,847 shares in the last quarter. State Street Corp raised its stake in shares of Palvella Therapeutics by 206.3% in the fourth quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after purchasing an additional 283,211 shares in the last quarter. Finally, First Light Asset Management LLC lifted its holdings in shares of Palvella Therapeutics by 38.3% during the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after acquiring an additional 271,617 shares during the period. Institutional investors and hedge funds own 40.11% of the company’s stock.

Insider Buying and Selling

In related news, Director Christopher P. Kiritsy sold 313 shares of the stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the transaction, the director owned 250 shares in the company, valued at approximately $39,250. This represents a 55.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $327,860.34. This trade represents a 66.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,917 shares of company stock worth $1,180,309 over the last quarter. 17.20% of the stock is owned by corporate insiders.

Palvella Therapeutics Stock Down 0.6%

Shares of NASDAQ:PVLA opened at $151.34 on Thursday. The company’s fifty day simple moving average is $148.65 and its 200 day simple moving average is $131.34. Palvella Therapeutics, Inc. has a 12 month low of $53.30 and a 12 month high of $161.38. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -31.33 and a beta of -0.25.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35). Research analysts expect that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PVLA has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Stephens reiterated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, Canaccord Genuity Group set a $232.00 price objective on Palvella Therapeutics in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $209.14.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.